Literature DB >> 1336617

Prevalence in two mexican cities of human papillomavirus DNA sequences in cervical cancer.

M L González-Garay1, H A Barrera-Saldaña, L B Avilés, L M Alvarez-Salas, P Gariglio.   

Abstract

In Mexico, about 30% of all malignant tumors in women are uterine cervix carcinomas. It is one of their main causes of death. We have previously shown that in Mexico City, 31% (5/16) of the analyzed tumoral samples contained HPV-16 DNA sequences. We have now extended this observation in Mexico City and included the city of Monterrey and found that the prevalence of HPV-16 is similar in both: 26% (6/23) for Monterrey and 29% (4/14) for Mexico City. HPV-18 was detected in only 10% (1/10) and 7% (1/14) of the tumors in these two populations when assayed with an HPV-18 specific probe. In both cities, the majority of the samples analyzed (including samples from the four stages of severity of the disease) contained integrated papillomavirus DNA sequences. Our results suggest that the mexican population contains a rather low proportion of HPV-16 and HPV-18 sequences in uterine-cervix carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336617

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  2 in total

1.  Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.

Authors:  I Nindl; L Benitez-Bribiesca; J Berumen; N Farmanara; S Fisher; G Gross; L Lopez-Carillo; M Müller; M Tommasino; A Vazquez-Curiel
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 2.  Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis.

Authors:  Agustín Ciapponi; Ariel Bardach; Demián Glujovsky; Luz Gibbons; María Alejandra Picconi
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.